RecruitingNot ApplicableNCT06909604

Al18F-HER2-BCH PET in Breast Patients Treated With Neoadjuvant Therapy

Al18F-HER2-BCH PET/CT to Predict Response in Breast Patients Treated With Neoadjuvant Therapy

Sponsor

Peking University Cancer Hospital & Institute

Enrollment

50 participants

Start Date

Jan 1, 2025

Study Type

INTERVENTIONAL

Conditions

Breast Cancer

Summary

To use the molecular PET radionuclide (F-18) labelled HER2 Affibody to evaluate the predictive and prognostic value in breast patients treated with neoadjuvant therapy

Eligibility

Min Age: 18 Years

Inclusion Criteria5

Aged ≥18 years old; ECOG 0 or 1;
Patients with newly diagnosis HER2 positive or suspicious positive tumors;
Receives neoadjuvant therapy
Has adequate cardiac, bone marrow, renal, hepatic and blood clotting functions;
Life expectancy \> 3 months -

Exclusion Criteria6

Significant hepatic or renal dysfunction;
Is pregnant or ready to pregnant;
Cannot keep their states for half an hour;
Refused to join the clinical research;
Suffering from claustrophobia or other mental disorders;
Any other situation that researchers considered it unsuitable to participate in the trial.

Interventions

RADIATIONHER2 expression of PET imaging

Evaluate the diagnostic potential of HER2 imaging using 18F-labelled HER2 affibody , evaluate the predictive and prognostic value of HER2 PET imaging in bladder cancer patients treated with neoadjuvant therapy